ここから本文です

ファイザーとメルクのバベンシノはセカンドライン肺癌P3治験で失敗した様子。

The partners reported this morning that their Phase III lung cancer study JAVELIN Lung 200 failed the primary endpoint for overall survival comparing Bavencio (the PD-L1 avelumab) against docetaxel in second-line lung cancer, a major field for all the players in this particular field.